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We identified 11,602 patients receiving chemotherapy in public hospitals. During 
follow-up, 7,417 patients (63.9%) received expensive drugs at least once, including 
mostly pemetrexed (57.5%), bevacizumab (16.9%), or topotecan (7.2%); these patients 
were significantly more likely women and younger than the rest of the cohort 
(p< 0.0001). Conversely, all selected comorbidities were associated with lower rates 
of administration i.e. chronic renal failure, diabetes, hypertension, COPD and other 
respiratory diseases (p< 0.0001). Taking as reference patients from affluent areas, we 
observed lower rates of access in intermediary affluent, intermediary deprived and 
deprived areas. After multivariate adjustment, odd ratios were 0.85 [95%:0.75–0.95], 
0.82 [95%:0.74–0.92] and 0.80 [95%:0.71–0.89], respectively. ConClusions: Even in 
a health care system organized to ensure a high degree of equity in medical care, 
we found indications of a socioeconomic gradient in innovative anticancer drugs 
access in lung cancer.
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objeCtives: Tight public budget constraints have accelerated the debate on the 
extent of prescribed medications that are publicly covered in Spain, a country with 
one of the lowest percentage of OTC sales over total drugs sales. The objective 
of this study is to examine the economic impact of payer policies consisting on 
a hypothetical Rx-to-OTC switch of 5% of currently publicly covered prescription 
drugs for mildest conditions. Methods: A decision model is used to estimate the 
economic impact of the switch. Both third-party-payer and societal perspectives 
are adopted, using a five-year timeframe, both at regional (17 regions) and national 
levels. The model is inspired by a previous ones in European countries, but the 
timeframe and the effects measured have been further developed for the sake of 
robustness and better reflection of the current Spanish reality. The effects, meas-
ured in monetary units, include those regarding to quality of primary care, labor 
productivity, the opportunity cost for non-working populations, and financial bur-
den of pharmaceutical expenditure. Resources allocated to improving responsible 
self medication are also accounted for. The study analyses the effects on different 
stakeholders (patients, NHS, and society). Finally, it includes both a standard and 
a probabilistic sensitivity analysis. Results: The switch results in a 3.125€ millon 
societal effect, explained by improving quality of primary health care (2.258M€ ), 
improving labor productivity (507), optimization of non working patients’time (579) 
and a reduction of public expenditure on publicly covered medication (979). On 
the other hand, there are negative effects from increasing privately funded drugs 
(1.165) and the cost of improving self-care (35). Sensitivity analyses confirm overall 
results (p< 0,01). ConClusions: Under increasing budgets constraints, switch-
ing drugs for mild conditions may be a solution with positive societal net effects, 
although the distribution of the impacts among stakeholders might make the ini-
tiative unpopular.
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objeCtives: Since the introduction of orphan legislation the number of orphan 
drugs has dramatically increased. The objective of the study is to compare 
orphan designations and approvals in the EU, USA and Japan. Methods: The 
list of molecules with orphan status, as well as the list of approved orphan drugs 
(ODs) in the USA, EU and Japan were identified from the websites of Food and 
Drug Administration (FDA) of the USA, the European Medicines Agency (EMA), and 
National Institute of Biomedical Innovation, Health and Nutrition. All available 
details on orphan designations and approvals were extracted. Results: By June 
2015, 3465 orphan designations were granted in the USA, 1503 in the EU and 399 
in Japan. More than 60% of orphan designations led to an approval in Japan, about 
14% in the USA, and only 7% in the EU. The median delay between granting an 
orphan designation and approval was more than three years in the USA and EU, 
and about two years in Japan. EMA publishes the most detailed information on 
orphan designations and OD approvals. Unlike the USA and Japan, the details on 
refusals in orphan status or approvals together with decision rationale are available 
in the EU. ConClusions: A higher number of ODs has been approved in the USA. 
However, many of them have been discontinued, particularly among ODs approved 
before 2000. The relatively small number of ODs approved in the EU might be related 
to the lower financial support of ODs provided in the EU compared to the USA and 
Japan. A noticeably high commercialisation rate is observed in Japan, which can be 
associated with the feasibility criteria applied to the drugs submitting for orphan 
designation on the one hand, and with the arrival on Japan market of molecules 
already commercialized in other countries on the other.
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objeCtives: The objectives are to present the scorecard HTA system used in Romania 
from July 2014 and the results in terms of access of new therapies at reimburse-
ment. Methods: The authors studied the scorecard HTA legislation and the relation-
ship with the health-care environment from the last 2 years considering: the evolution 
of the Romanian HTA methodologies, the HTA process and the implications in other 
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objeCtives: Patient registries are a good source of evidence for health-care pro-
viders, payers and regulators requiring real-world data for evidence-based deci-
sion making. This review aimed to identify and assess key characteristics of the 
heart failure (HF) registries reporting patients’ data from five European Union (EU5) 
countries. Methods: HF registries were identified through a systematic search of 
Embase and PubMed databases. Inclusion criteria were data on HF patients from 
EU5 countries (France, Germany, Italy, Spain, and the UK) and patient counts ≥ 1000. 
Registry publications and websites were assessed for availability of information on 
patient characteristics, disease management, resource use, treatment outcomes and 
funding agency. Results: Of 23 identified registries reporting data for HF patients, 
43% were multinational while 57% were national-level registries. Twelve registries 
each collected data from Spain, Germany, and Italy and eight and six registries from 
France and the UK, respectively. Data was collected for patients with acute HF only 
(31%), chronic HF only (43%), and both acute and chronic HF (26%) in the identified 
registries. Number of included patients varied from 1037 to 25,000 with the average 
follow-up ranging from 3-53 months. Data was available for patient demographics 
(in 100% registries), comorbidities (87%), diagnosis and disease classification (78%), 
mortality (78%), hospitalisation (96%), prescribed drugs (100%), and patient-reported 
outcomes (17%). Registries also collected data on specific diagnostic tools (blood 
pressure, ECG, blood tests, biomarkers, imaging, and renal function tests), treat-
ment procedures (revascularisation, catheterization, and transplant), resource use, 
adverse events, and cost. Of these registries, 65% initiated during last 10 years and 
61% were industry-funded. ConClusions: Registries are a rich source of real-
world information on HF patients which can be turned into actionable insights 
for important health-care decisions. Rise in the number of HF registries in recent 
years and industry funding indicates increased interest of stakeholders in these 
registries’ data.
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objeCtives: In April 2014, the European Medicines Agency (EMA) announced an 
adaptive pathways pilot enabling initial approval of a medicine for a restricted 
patient population with very high unmet need based on early clinical studies. 
Progressive adaptations of the marketing authorisation would expand access to 
broader patient populations based on subsequent data. However, such an adaptive 
license may pose a problem for payer bodies, many of which currently require a 
long time period to review medicines under strict clinical and economic criteria. 
This research aims to evaluate how ready major European current payer systems 
would be to encompass EMA adaptive pathways. Methods: Key European payer 
bodies from the EU5 (NICE, SMC, HAS, IQWiG/G-BA, AIFA and AEMPS were scored by 
PAREXEL’s Commercialization panel of pricing and reimbursement experts on 4 key 
criteria: (1) speed of appraisal, (2) flexibility to clinical data appraisal approach, (3) 
flexibility to economic data appraisal approach, and (4) no additional local/regional 
access hurdles as either high (2 points), medium (1 point) or low (0 points). Results: 
Out of a possible 8 points, HAS scored the highest (7) followed by SMC (6), AIFA (5), 
AEMPS (5), IQWiG (4) with NICE the lowest (2). Low scores for NICE were driven by 
its long duration for decision-making alongside rigid adherence to ICER thresholds. 
Higher scores for SMC were based on their much faster appraisals and flexibil-
ity through the new PACE process. AIFA and AEMPS both scored moderately with 
positive flexibility in their approaches tempered by additional local/regional access 
hurdles. In Germany, rigid adherence to direct comparative trial data versus the 
relevant comparator limited positive scoring. ConClusions: some payers (most 
notably NICE) will need to make significant changes to their appraisal processes 
In order for early market approval under adaptive pathways to translate into early 
reimbursement and payer access
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objeCtives: Lung cancer survival is socioeconomically patterned, and socioeco-
nomic inequalities in receipt of treatment have been demonstrated in several coun-
tries. In the hospitals, many innovative anticancer drugs are too expensive to be 
funded through a Diagnosis-Related Group (DRG) of chemotherapy administration. 
In France, such drugs are fully reimbursed up to national reimbursement tariffs 
(extra-DRG funding) to ensure equity of access. Our aim was to analyze the access 
of patients to innovative drugs according to social deprivation index. Methods: 
A retrospective cohort study was constituted with all patients having a diagnosis 
of metastatic lung cancer in the French National hospitals databases (PMSI) during 
year 2011. Patients’ data were linked to allow a two-year follow-up period. Because 
extra-DRG data were not available for private hospitals, our analysis was restricted 
to patients benefiting from chemotherapy in public hospitals only. In addition 
of demographic characteristics, comorbidities, and treatment, we assigned each 
patient to social deprivation index based on their postcode of residence. Results: 
